Weiqi Hong, Hong Lei, Dandan Peng, Yuhe Huang, Cai He, Jingyun Yang, Yanan Zhou, Jian Liu, Xiangyu Pan, Haiying Que, Aqu Alu, Li Chen, Jiayuan Ai, Furong Qin, Binhan Wang, Danyi Ao, Zhen Zeng, Ying Hao, Yu Zhang, Xiya Huang, Chunjun Ye, MinYang Fu, Xuemei He, Zhenfei Bi, Xuejiao Han, Min Luo, Hongbo Hu, Wei Cheng, Haohao Dong, Jian Lei, Lu Chen, Xikun Zhou, Wei Wang, Guangwen Lu, Guobo Shen, Li Yang, Jinliang Yang, Jiong Li, Zhenling Wang, Xiangrong Song, Qiangming Sun, Shuaiyao Lu, Youchun Wang, Ping Cheng, Xiawei Wei
Urgent research into innovative severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccines that may successfully prevent various emerging emerged variants, particularly the Omicron variant and its subvariants, is necessary. Here, we designed a chimeric adenovirus-vectored vaccine named Ad5-Beta/Delta. This vaccine was created by incorporating the receptor-binding domain from the Delta variant, which has the L452R and T478K mutations, into the complete spike protein of the Beta variant. Both intramuscular (IM) and intranasal (IN) vaccination with Ad5-Beta/Deta vaccine induced robust broad-spectrum neutralization against Omicron BA...
May 2024: MedComm